Sun Pharmaceutical is currently trading at Rs. 569.00, up by 12.45 points or 2.24% from its previous closing of Rs. 556.55 on the BSE.
The scrip opened at Rs. 559.00 and has touched a high and low of Rs. 570.00 and Rs. 556.00 respectively. So far 79,000 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 583.00 on 16-Sep-2013 and a 52 week low of Rs. 328.00 on 15-Nov-2012.
Last one week high and low of the scrip stood at Rs. 572.95 and Rs. 535.55 respectively. The current market cap of the company is Rs. 1, 17,845 crore.
The promoters holding in the company stood at 63.65% while Institutions and Non-Institutions held 25.96% and 10.39% respectively.
Sun Pharmaceutical Industries’ subsidiary has been granted the US Food and Drug Administration (USFDA) final approval for its Abbreviated New Drug Applications (ANDA) for generic version of Prevacid, Lansoprazole Delayed-Release Capsules USP, 15 mg and 30 mg.
Lansoprazole Delayed-Release Capsules USP, 15 mg and 30 mg are therapeutic equivalents of Takeda’s Prevacid Delayed-Released Capsules. These Capsules have annual sales of approximately $430 million in the US. Lansoprazole Delayed-Release Capsules USP is indicated for short-term treatment (for 4 weeks) for healing and symptom relief of active duodenal ulcer. Prevacid is a registered trademark of Takeda Pharmaceuticals U.S.A., Inc.
Sun Pharmaceutical Industries is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: